Who are Solaraze 3% Topical Gel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Adapalene/Benzoyl Peroxide Gel 0.3-2.5%, Minocycline plus tretinoin, Tretinoin cream 0.005%, adapalene gel, 0.3%, Adapalene + benzoyl peroxide samples, Duobrii®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/solaraze-3-topical-gel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Solaraze 3% Topical Gel — Competitive Intelligence Brief

Solaraze 3% Topical Gel (Solaraze 3% Topical Gel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: retinoid. Area: Dermatology.

phase 3 retinoid retinoic acid receptors Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Solaraze 3% Topical Gel (Solaraze 3% Topical Gel) — Encube Ethicals Pvt. Ltd.. Solaraze 3% Topical Gel is a topical gel formulation of tazarotene, a retinoid that modulates the expression of genes involved in cell proliferation and differentiation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Solaraze 3% Topical Gel TARGET	Solaraze 3% Topical Gel	Encube Ethicals Pvt. Ltd.	phase 3	retinoid	retinoic acid receptors
Adapalene/Benzoyl Peroxide Gel 0.3-2.5%	Adapalene/Benzoyl Peroxide Gel 0.3-2.5%	Derm Research, PLLC	marketed	Retinoid + peroxide combination	Retinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide)
Minocycline plus tretinoin	Minocycline plus tretinoin	Derm Research @ 888 Inc.	marketed	Tetracycline antibiotic + retinoid combination	Bacterial ribosome (minocycline); retinoic acid receptors (tretinoin)
Tretinoin cream 0.005%	Tretinoin cream 0.005%	Hexsel Dermatology Clinic	marketed	Retinoid	Retinoic acid receptors (RAR-α, RAR-β, RAR-γ)
adapalene gel, 0.3%	adapalene gel, 0.3%	Galderma R&D	marketed	Retinoid (third-generation)	Retinoic acid receptors (RARγ, RARα, RARβ)
Adapalene + benzoyl peroxide samples	Adapalene + benzoyl peroxide samples	Wake Forest University	marketed	Retinoid + peroxide combination	Retinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide)
Duobrii®	Duobrii®	Icahn School of Medicine at Mount Sinai	marketed	Topical corticosteroid and retinoid combination	Glucocorticoid receptor (halobetasol); retinoic acid receptors (tazarotene)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Solaraze 3% Topical Gel — Competitive Intelligence Brief. https://druglandscape.com/ci/solaraze-3-topical-gel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab